with patients, and expensive, numerous indirect or "tubeless" tests of pancreatic function (e.g., fecal chymotrypsin, bentiromide, and pancreolauryl tests) have been introduced as alternatives [1] .Among them, the 72-h fecal fat analysis still remains the standard test for diagnosing and quantifying fat malabsorption in chronic pancreatitis [2] , even though it is both insensitive and nonspecific in the diagnosis of chronic pancreatitis [3, 4] . Furthermore, fecal fat analysis is also time consuming, requires special laboratory equipment, and is unpopular among the laboratory staff. Among tubeless pancreatic function ranges from 72% to 90%, and its specificity, which appears to depend on the selection of the control subjects studied, ranges from 49% to 90% [5] [6] [7] [8] [9] [10] [11] [12] [13] . As shown in Fig. 1, no fecal fat content, whereas fecal immunoreactive elastase was not affected by substitution therapy (Fig. 2) .
Elastase release in duodenalaspirate. There was a good correlation (Fig. 3) between the output of elastase and that of amylase, In the less severely impaired patients, without steatorrhea, the diagnostic sensitivity decreased to 88%. In the same groups of patients with chronic pancreatitis, the diagnostic sensitivity for chymotrypsin was 91%, whereas its diagnostic specificity was only 91% (with steatorrhea) and 56% (without steatorrhea) ( Table 2 ).
Discussion
The objective of the present study was the evaluation of fecal immunoreactive elastase for the diagnosis and differential diag- nosis of pancreatic exocrine insufficiency. This test is highly specific for human pancreatic elastase, because elastase does not interfere with pancreatic enzyme preparations.
Thus, in contrast to fecal chymotrypsin tests, the results are not affected by pancreatic enzyme replacement therapy. A strong correlation was found between the duodenal secretion of elastase and that of amylase, lipase, and trypsin in the secretin-pancreozymin test. Considering the relationship between enzymatic outputs in feces and in pancreatic juice after CCK-PZ stimulation, we found a satisfactory correlation for elastase. As with fecal chymotrypsin, the immunoreactive elastase test is stable in feces for several days, which offers the possibility that stool samples from outpatients can be mailed to diagnostic centers. In contrast to chymotrypsin, however, which has a fecal recovery of only 0.5% of its activity in pancreatic juice, the degradation of immunoreactive elastase is negligible during intestinal passage, resulting in a five-to sixfold greater concentration than that in pancreatic juice [14] .
Determination of fecal chymotrypsin has been accepted as an indirect test for pancreatic function. Measurement of fecal chymotrypsin can also be used to detect pancreatic insufficiency in children with cystic fibrosis. The test has some advantages over other tubeless tests: The test is simple to perform when an 
